title: An HIV-infected Pregnant Woman Treated with the Long-term Administration of Antiretroviral Therapy Including Raltegravir.
abstract: A 27-year-old HIV-infected pregnant Japanese woman was admitted to our hospital at gestational week 14. The patient's HIV viral load was 71,000 copies/mL, and her CD4 cell count was 147 cells/mm(3). Zidovudine, lamivudine, and lopinavir/ritonavir were administered at gestational week 18. Because the viral load increased to 222,000 copies/mL at the initiation of antiretroviral therapy, we added raltegravir. The decrease in the viral load was satisfactory, and a caesarean delivery was performed. Although the plasma concentration of raltegravir in the neonate was significantly high (2,482 ng/mL), no adverse event was confirmed. There was no evidence of the mother-to-child transmission of HIV.
authors.affiliation: Department of Infection Control and Prevention, Kurume University School of Medicine, Japan.
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Yaita
authors.forename: Shigeru
authors.initials: S
authors.lastname: Inoue
authors.forename: Takashi
authors.initials: T
authors.lastname: Horinouchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kinoshita
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Unno
authors.forename: Osuke
authors.initials: O
authors.lastname: Iwata
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Gotoh
authors.forename: Mikio
authors.initials: M
authors.lastname: Ishibashi
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Sakai
authors.forename: Kenji
authors.initials: K
authors.lastname: Masunaga
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Masaki
authors.initials: M
authors.lastname: Tominaga
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007231:Infant, Newborn; D019259:Lamivudine / Q000627:therapeutic use; D061466:Lopinavir / Q000627:therapeutic use; D011247:Pregnancy; D012367:RNA, Viral / Q000097:blood; D000068898:Raltegravir Potassium; D019438:Ritonavir / Q000627:therapeutic use; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D061466:Lopinavir; D019259:Lamivudine; D000068898:Raltegravir Potassium; D015215:Zidovudine; D019438:Ritonavir